The Important Role that Biopharmaceutics Plays in Accelerating Early-Phase Drug Development
Pharmaceutical Technology
FEBRUARY 23, 2023
Many compounds present sub-optimal pharmacokinetic (PK) data (either predicted from in-vitro and pre-clinical data or measured in the clinic), such as poor exposure (leading to high doses), large variability, short half-life requiring more than once-a-day dosing, or C max -related adverse events (AEs).
246 
Let's personalize your content